



ACCC 43rd  
ANNUAL MEETING

# CANCERSCAPE

BUSINESS & POLICY, VALUE & QUALITY

**MARCH 29–31, 2017**

RENAISSANCE WASHINGTON, DC DOWNTOWN HOTEL  
Washington, D.C.

Given this rapidly changing and turbulent political landscape, the future of healthcare is more unclear than ever. **CANCERSCAPE** will bring together political experts and key stakeholders from leading national organizations to share insights on how value-based care, drug pricing reform, coverage under the Affordable Care Act (ACA), and changes to Medicare will impact your patients and program.

**REGISTER  
TODAY!**

**Save \$100 with special early bird rates  
through Friday, February 17, 2017!**

# CAPITOL HILL DAY WEDNESDAY, MARCH 29

It's now more important than ever to engage with your Congressional representatives and make your voice heard on Capitol Hill. No need to be a "policy expert" or familiar with specific legislation to advocate for improved funding and access to quality oncology care. Capitol Hill Day is an opportunity to share **YOUR STORY** with lawmakers so they understand how policy decisions are affecting cancer care in **YOUR COMMUNITY**.

The ACCC policy team will host webinars and onsite training to help you prepare for your Congressional meetings. Capitol Hill Day is included with your **CANCERSCAPE** registration. Just check the "Capitol Hill Day" box to indicate your participation when you register.

**Who Should Attend?** **CANCERSCAPE** is a collaborative educational and networking opportunity for the multidisciplinary cancer care team.

The agenda will reflect breaking news from the new administration. For the latest session and speaker updates, visit [acc-cancer.org/cancerscape](http://acc-cancer.org/cancerscape).

## AGENDA AT A GLANCE

### TUESDAY, MARCH 28

4:00 – 6:00 pm Capitol Hill Day Training and Cocktail Reception

### WEDNESDAY, MARCH 29

7:30 – 9:00 am Capitol Hill Day Registration, Breakfast, and Training

10:00 am – 4:00 pm Congressional Meetings and Lunch

5:00 – 6:00 pm New Member Meet and Greet

6:00 – 7:00 pm Welcome and Opening Reception

### THURSDAY, MARCH 30

7:00 – 8:00 am Breakfast in the Exhibit Hall

8:00 am – 5:15 pm Sessions

6:00 – 8:00 pm Cherry Blossom Walking Tour (optional)

### FRIDAY, MARCH 31

8:00 – 8:45 am Breakfast and ACCC House of Delegates

8:45 am – 12:15 pm Sessions

12:15 – 1:15 pm Lunch and Meeting Conclusion

**"Capitol Hill Day was exceptional. It was well organized, the staff was prepared, background information was concise, and there was a clear message that could be delivered. It was a great experience."** — 2016 PARTICIPANT

## AGENDA HIGHLIGHTS THURSDAY, MARCH 30 & FRIDAY, MARCH 31

### KEYNOTE SESSION

#### The State of Healthcare Under the New Administration

**Kavita Patel, MD, MS, FACP**, *The Brookings Institution*

**Dan Todd, JD**, *Todd Strategy*

**Leah Ralph, ACCC (MODERATOR)**

A 360° look at the healthcare landscape under the new administration from a Democrat and Republican perspective with insights on what oncology providers can expect in terms of reimbursement, alternative payment models, quality reporting, and more.

### GENERAL SESSIONS

#### The State of Today's Cancer Programs

**Lindsay Conway, MEd**, *The Advisory Board Company*

An analysis of major market forces impacting oncology and the implications for strategic planning, financial forecasting, and budgeting; service line quality improvement initiatives; and patient access.

#### The ACA Under Trump: What's Staying, What's Going & What about Those State Exchanges?

**Alan Balch, PhD**, *Patient Advocate Foundation*

**Elizabeth Carpenter**, *Avalere Health*

**Clara Lambert**, *Cowell Family Cancer Center*

The incoming Trump Administration and Congress have named repealing the ACA as one of their top priorities for 2017. Our expert panel will help translate what these changes might mean for your cancer program. Plus, learn practical strategies to help ensure that your patients maintain adequate coverage during a time of potential upheaval.

**"We must come together to discuss the issues that affect us all and understand the options we can employ to make a difference and benefit our patients."** — 2016 PARTICIPANT

## AGENDA HIGHLIGHTS (continued)

### Value-Based Frameworks— Everything Your Cancer Program Needs to Know

**Stephen S. Grubbs, MD**, *American Society of Clinical Oncology (ASCO)*

**Ali McBride, PharmD, MS, BCPS, BCOP**,  
*The University of Arizona Cancer Center*

Find out how policymakers and providers will be expected to use value-based tools as part of broader efforts to reduce healthcare costs and improve care, including the implications for patients.

### What Cancer Programs Can Do to Thrive—Not Just Survive—MACRA

**Robin Zon, MD, FACP**, *Michiana Hematology Oncology, PC*

Starting in 2017, clinicians will be required to report on new measures under the Quality Payment Program (QPP) created under MACRA. Learn how to put together a practice leadership team to participate in mandatory quality reporting, improve meaningful use performance, reduce hospitalizations, make smart drug purchasing decisions, and code for all ICD-10 comorbidities.

### Drug Pricing Under the Trump Administration

**Jessica Turgon, MBA**, *ECG Management Consultants*

While President Trump has vowed to control drug costs under his administration, private payers and providers are acting now to address this through transparency mandates and outcome-based drug pricing. Learn the latest federal policy options for tackling rising drug costs and how your program can proactively plan for these changes.

### Site-Neutral Payment Policy— How It May Impact Your Program

**Beth L. Roberts**, and **Elizabeth Halpern**,  
*Hogan Lovells US LLP*

Intending to align hospital outpatient department and physician office reimbursement, this payment methodology will result in reimbursement cuts for several hospital-based outpatient procedures. Learn how this policy will impact your cancer program, especially for those planning new construction or satellite locations, and the broader long term impact on the cancer delivery infrastructure.

### 340B—The Good, the Bad, and the Ugly

**Bonnie Kirschenbaum, MS, FASHP, FCSHP**, *American Society of Health-System Pharmacists (ASHP)*

An update on the 340B Drug Pricing Program, including an analysis of last year's proposed mega-guidance and what it means for hospitals, practices, and pharmaceutical companies. Then hear strategies to help providers manage multiple vendors, standardize processes, and maintain compliance.

### TRACK 1: BUSINESS & POLICY

#### Alternative Payment Models in Radiation Oncology

**Anne Hubbard, MBA**, *American Society for Radiation Oncology (ASTRO)*

Hear from ASTRO about their development of a radiation oncology-specific alternative payment model—and how ACCC members can support the process. Plus, learn how ASTRO's new Accreditation Program for Excellence (APEX) can help your program meet the radiation therapy components of the CoC and NAPBC accreditation programs.

#### Translating Lessons Learned from the Oncology Care Model to Other APMs

**Nikolas Buescher, MHS**, and **Elizabeth Horenkamp, MD**, *Lancaster General Hospital*

**Wendalyn G. Andrews**, *The University of Arizona Cancer Center (MODERATOR)*

While the future of the Oncology Care Model may be uncertain, implementing alternative payment models will remain critical to your program's success. An administrator and physician champion share challenges and lessons learned for practice redesign requirements, cultural buy-in, commercial provider partnerships, and opportunities for improvement.

#### Implementing a Specialty Pharmacy: Two Model Programs

Hear from a community-owned hospital that used Lean Six Sigma methodology to develop a formal, physician-driven protocol for prescribing and dispensing oral oncolytics, and a multi-site physician practice which established 12 in-office dispensing specialty pharmacies to improve patient access, reduce out-of-pocket expenses, and improve care coordination.

### TRACK 2: VALUE & QUALITY

#### Advancing High-Value Early Breast Cancer Care

**Angie Meillier, RN, MS, CPPM**, *Abbott Northwestern Piper Breast Center*

This ACCC Cancer Program Member implemented multiple evidence-based quality improvement (QI) strategies, such as shared decision-making in treatment planning; use of short-course radiation planning; and reduction of re-excision rates. See how they achieved reduced costs of care and improved patient quality of life.

#### An Advanced Practice Provider-Led Symptom Management Clinic

**Johanna T. Crock, MSN, OCN, AGNP-C**, and **Katie Snell, MSN, AOCN, AGNP-C**, *CARE Clinic | Clinical Assessment and Rapid Evaluation, University of Colorado Hospital Cancer Center*

Hear how this clinic provides evidence-based symptom management for patients with acute and chronic cancer, resulting in fewer unnecessary ED visits; reduced inpatient length of stay and admissions; and improved clinical outcomes.

#### Improve Your Data Collection— Streamline Your Accreditation & Quality Reporting Processes

**Toni Hare, RHIT, CTR**, *CHAMPS Oncology*

**Sylvia Radziszewski, RRT, MBA**, *Summa Health Cancer Institute*

Learn innovative cancer registry solutions to streamline the accreditation process, practical strategies to meet cancer program standards and accreditation requirements, and tips for transforming your data into quality records that can support the move to value-based care and alternative payment models.

#### Robotic Radiosurgery in the Community Setting: Redefining Standards in Quality Assurance

**Jacob Gersh, PhD**, *Gibbs Cancer Center*

See how this new technology was implemented through a quality assurance (QA) program aimed at improving patient access; maintaining treatment modality accuracy; reducing staffing and operating costs, machine downtime, and time between initial consult and treatment.



Association of Community Cancer Centers

1801 Research Blvd. Suite 400

Rockville, MD 20850

accc-cancer.org



## REGISTRATION RATES

**SAVE \$100 OFF REGISTRATION RATES UNTIL FEBRUARY 17**

ACCC Member (all categories)	\$590
2nd Registrant* (provider only)	\$300
Non-Member	\$775
Industry Council Member	\$775
Industry/Company Non-Member	\$2,200

\*2nd Registrant Details:  
A member that registers for the meeting at the full rate may register a second person, member or non-member, from an institution or practice at a discounted rate.



## 5 EASY WAYS TO REGISTER


<b>ONLINE</b>	accc-cancer.org/cancerscape
<b>EMAIL</b>	membership@accc-cancer.org
<b>PHONE</b>	301.984.9496, ext. 200 or 216
<b>FAX</b>	301.770.1949
<b>MAIL</b>	1801 Research Blvd. Suite 400 Rockville, MD 20850

## HOTEL INFORMATION

Nestled in the nation's capital, this luxury hotel is just a stone's throw away from Capitol Hill, famous landmarks, must-see museums, and gourmet dining.

### Renaissance Washington, DC Downtown Hotel

999 9th St. NW  
Washington, D.C. 20001



**CANCERSCAPE** attendees may take advantage of a discounted rate of \$279/night, plus taxes. This rate is available through March 5, 2017 (subject to availability). To secure your room, please visit <http://bit.ly/ACCCDCHotel> or call 202.898.9000, and mention the ACCC Annual Meeting when booking.

## INDUSTRY MEMBERS

### Industry Advisory Council

Amgen Inc.  
Astellas Pharma US  
AstraZeneca  
Bayer HealthCare  
Pharmaceuticals  
Bristol-Myers Squibb  
Celgene Corporation  
Eisai Inc.  
Genentech, Inc.  
Janssen Biotech, Inc.  
Lilly Oncology  
Merck & Company  
Novartis Oncology  
Pfizer Oncology  
Sanofi Oncology  
Takeda Oncology  
Teva Oncology

### Emerging Companies Council

AbbVie  
Apobiologix  
ARIAD Pharmaceuticals  
Boehringer Ingelheim  
Pharmaceuticals, Inc.  
EMD Serono  
Incyte Corporation  
Ipsen  
Medivation, Inc.  
Merrimack Pharmaceuticals  
Mylan Pharmaceuticals  
Pfizer Biosimilars  
Pharmacyclics  
Sandoz  
Seattle Genetics  
Taiho Oncology  
Tesaro

### Technical Advisory Council

ION Solutions  
Walgreens



## CME/CE INFORMATION

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Medical and Nursing Education (IMNE) and Association of Community Cancer Centers (ACCC). IMNE is accredited by the ACCME to provide continuing medical education for physicians. IMNE designates this educational activity for a maximum of 10.5 AMA PRA Category 1 Credits.™ Physicians should only claim credit commensurate with the extent of their participation in the activity.

## CNE CREDIT

This activity has been planned and implemented through the joint providership of IMNE and ACCC. IMNE is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC's) Commission on Accreditation. This educational program provides 10.5 contact hours of continuing nursing education credit. If you have any questions regarding the CME or CE credit being offered for this meeting, please contact IMNE at [info@imne.com](mailto:info@imne.com).

## DISCLAIMER

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of ACCC, its affiliated chapters, or IMNE.



Get social with @ACCCBuzz! Join the conversation on Facebook and Twitter using #CANCERSCAPE